# Phase III Study of Hemospan® for Treating Hypotension in Hip Arthroplasty

> **NCT00420277** · PHASE3 · COMPLETED · sponsor: **Sangart** · enrollment: 462 (actual)

## Conditions studied

- Hypotension
- Ischemia

## Interventions

- **DRUG:** Hemospan (MP4OX)
- **DRUG:** Voluven (HES 130/0.4)

## Key facts

- **NCT ID:** NCT00420277
- **Lead sponsor:** Sangart
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02
- **Primary completion:** 2008-03
- **Final completion:** 2008-04
- **Target enrollment:** 462 (ACTUAL)
- **Last updated:** 2013-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00420277

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00420277, "Phase III Study of Hemospan® for Treating Hypotension in Hip Arthroplasty". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00420277. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*